

Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients

NCT07294209

Status	RECRUITING
Phase	Phase 4
Sponsor	Southwest Hospital, China
Enrollment	798 participants

Key Eligibility Criteria

Inclusion (6)

- Age \geq 70 years;
 - Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1d NIHSS \geq 5); if NIHSS $<$ 5, patients have to be with at least a measurable deficit on motor power (upper or lower limbs \geq 1);
 - Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
 - Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
 - Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
- ... and 1 more (see full listing online)

Exclusion (20)

- Imaging demonstrates multi-lobar infarction (hypodensity $>$ 1/3 cerebral hemisphere);
 - Acute bleeding diathesis or allergy to tenecteplase, including but not limited to
 - Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
 - Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
 - Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) $>$ 1.7 or Prothrombin time (PT) $>$ 15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigatran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
- ... and 15 more (see full listing online)

Locations (48 total)

Southwest Hospital, Chongqing, China, Chongqing, Chongqing Municipality, China
Anshan Changda Hospital, Anshan, China
Anyang People's Hospital, Anyang, China
... and 45 more locations